Work

Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.2032

Authors: Eudocia Quant Lee, Alona Muzikansky, David A. Reardon, Jorg Dietrich, Lakshmi Nayak, Dan G. Duda, Ugonma Nnenna Chukwueke, Rameen Beroukhim, Lisa M. Doherty, Caroline Kane, Debra C. LaFrankie, Brittney Fontana, Jennifer Stefanik, Sandra Ruland, Victoria Caruso, Jennifer Bruno, Sarah C. Gaffey, Patrick Y. Wen

Institutions: Dana-Farber Cancer Institute, Massachusetts General Hospital, Harvard University, Dana-Farber/Harvard Cancer Center, Dana-Farber Brigham Cancer Center

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2889626527

Cites:

Cited by: 7

Related to: 10